Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.

Ji YI, Lee BY, Kang YJ, Jo JO, Lee SH, Kim HY, Kim YO, Lee C, Koh SB, Kim A, Lee JY, Jung MH, Ock MS, Cha HJ

Pathology oncology research : POR10 Oct 2012Cited by 12 (Europe PMC)

PMID23055022DOI10.1007/s12253-012-9574-0PepBankPUB-23055022

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In primary ovarian cancers, Tβ4 expression was higher than in normal controls.
In plain wordsIn ovarian cancer tissue, the body's own Tβ4 levels were higher than in normal tissue.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 expression in primary ovarian cancer
Study
n: not reported in source
Comparator
Normal ovaries
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
Tβ4 is overexpressed in primary ovarian cancers
1 context sentence(design, population, supporting numbers)
Summary · context
The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2305502201
02HumanEndogenous levelObservational studyOther
In primary stomach cancers, Tβ4 was not overexpressed compared with normal controls.
In plain wordsIn stomach cancer tissue, the body's own Tβ4 levels were not higher than in normal tissue.
Peptide
Thymosin beta-4 (human)
Outcome
No significant changeTβ4 expression in primary stomach cancer
Study
n: not reported in source
Comparator
Normal stomachs
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
but not in primary stomach cancers, when compared with normal controls.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2305502202
03HumanEndogenous levelObservational studyOther
Tβ4 levels in metastatic stomach cancers to the ovary were significantly higher than in normal stomachs and primary stomach cancers.
In plain wordsIn stomach cancer that spread to the ovary, the body's own Tβ4 levels were higher than in normal or primary stomach tissue.
Peptide
Thymosin beta-4 (human)
Outcome
IncreaseTβ4 expression in metastatic stomach cancer to the ovary
Study
n: not reported in source
Comparator
Normal stomachs and primary stomach cancers
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
However, Tβ4 levels in metastatic stomach cancers to the ovary are significantly upregulated compared with levels in normal stomachs and primary stomach cancers.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2305502203
04HumanEndogenous levelObservational studyOther
In normal ovaries and normal stomachs, Tβ4 expression was weak but co-localized with CD133 expression.
In plain wordsIn normal ovary and stomach tissue, the body's own Tβ4 was weak but found in the same cells as CD133.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 co-localization with CD133 in normal ovaries and stomachs
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
The expression of Tβ4 in normal ovaries and normal stomachs was weak, but was co-localized with CD133 expression.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2305502204
05HumanEndogenous levelObservational studyOther
Tβ4 expression was co-localized with CD133 expression in primary ovarian carcinomas, metastatic ovarian cancers from stomach cancers and primary stomach cancers.
In plain wordsIn ovarian and stomach cancer tissue, the body's own Tβ4 was found in the same cells as CD133.
Peptide
Thymosin beta-4 (human)
Outcome
Not applicableTβ4 co-localization with CD133 in cancers
Study
n: not reported in source
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
Tβ4 expression was also co-localized with CD133 expression in primary ovarian carcinomas, metastatic ovarian cancers from stomach cancers and primary stomach cancers.
1 context sentence(design, population, supporting numbers)
Summary · context
The expression patterns of Tβ4 and CD133 were studied in normal ovaries, primary ovarian cancers, metastatic ovarian cancers, primary stomach cancers, and normal stomachs by Western blot and immunohistochemistry.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2305502205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 01:52 UTC
Study results updated
Version 1
12 Oct 2026, 18:17 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.